Market Analysts see Verastem Inc. [VSTM] gaining to $6. Time to buy?


VeraStim Inc. [NASDAQ: VSTM] The stock went on a downtrend as it fell more than -4.72% on Thursday, which is a one-week price drop of less than -16.53%. Company report on August 8, 2022 Verastem Oncology announces financial results for the second quarter of 2022 and highlights the company’s recent progress.

Top 5 cheap stocks to own right now

While finding safe stocks with the potential for huge gains isn’t always easy, we’ve found a few that can pay off well. In fact, within our report, Top 5 cheap stocks to own right nowIn this article, we have identified five stocks that we believe can increase in value even if you have $1,000 to invest.

Register here to get a free report now. .

sponsored by

Company-reported interim results from the RAMP 201 trial of VS-6766 +/- Defactinib in low-grade serous ovarian cancer; Continuous evaluation of both monotherapy and combination therapy with timing of choice of advanced treatment regimen driven by data maturity.

Verastem Oncology was awarded the Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to evaluate the combination of VS-6766 and Defactinib as well as the chemotherapy standard of care in front-line metastatic pancreatic cancer.

Over the past 12 months, VSTM stock is down -66.22%. Verastem Inc’s 1-year stock outlook is for a potential upside of 81.3. VSTM stock currently has an average equity rating of 2.00, and is trading near a bullish pattern in the stock market.

The stock has a market capitalization of $194.47 million, with 186.46 million shares outstanding and 186.00 million shares in current float. Compared to an average trading volume of 1.60 million shares, VSTM stock reached a trading volume of 2750,660 on the last trading day, which is why market watchers consider the stock to be active.

Educator’s opinion of Verastem Inc. [VSTM]:

Based on careful, fact-backed analysis by Wall Street experts, the current consensus on a target price for VSTM shares is $5.40 per share. Target price analysis and stock performance are usually carefully studied by market experts, and the current Wall Street consensus on VSTM stock is a set recommendation at 2.00. This rating represents a strong buy recommendation, on a scale of 1 to 5, where 5 means strong sell, 4 represents sell, 3 represents hold, and 2 indicates buy.

Alliance Global Partners has made a stock appreciation for Verastem Inc. , retaining their opinion of the stock as a buy, with their previous recommendation back on September 7, 2022. While these analysts held the previous recommendation, Cantor Fitzgerald cut their target price from $6 to $5. The new price target note was released on April 29, 2022, which is the official target price for Verastem Inc.’s stock. Previously, the target price had taken another increase to $5, while RBC Capital Mkts analysts maintained Outperform’s rating on VSTM stock.

The Average True Range (ATR) is set by Verastem Inc. at 0.09, with a price-to-sales ratio for VSTM stock in the last 12-month period at 62.73. The price-to-book ratio for the last quarter was 3.48, with the price-to-cash-to-cash ratio for the same quarter set at 0.49.

VSTM stock performance analysis:

VeraStim Inc. [VSTM] It fell into the red at the end of last week, fell in a negative direction and fell by -16.53. With this latest performance, VSTM shares are down -17.21% over the past four-week period, and also down -21.09% over the past six months – not to mention a -66.22% drop in the last year of trading.

Overbought and oversold stocks can be easily tracked by the Relative Strength Index (RSI), where an RSI result of over 70 is overbought, and any price below 30 indicates oversold conditions. The RSI of 50 represents neutral momentum in the market. The current RSI for the VSTM stock for the last two weeks was set at 36.03, with the RSI for the last one trading at 29.15, and the three-week RSI set at 40.05 for Verastem Inc. [VSTM]. The current moving average for the last 50 trading days for this stock is 1.1936 while it recorded at 1.1000 for the last trading week, and 1.4064 for the last 200 days.

An insight into the fundamentals of Verastem Inc.:

Operating margin for any stock indicates how profitable the investment is, and Verastem Inc. [VSTM] The equity’s current operating margin is -10372.28 and the gross margin is +66.01. Verastem Inc.’s net margin was reported. Currently at -11749.17.

The return on equity for this stock fell to -70.21, with the return on assets remaining at -54.14.

Verastem Inc.’s liquidity data is Interesting too, with the quick ratio at 4.90 and the current ratio at 4.90.


The company’s progress can be seen through the perspective of the EPS growth rate, while Wall Street analysts focus on forecasting the 5-year EPS growth rate for VSTM. When it comes to the stated value, analysts expect Verastem Inc.’s 5-year EPS growth rate to rise. to 1.74%.

VeraStim Inc. [VSTM] Insiders’ position details

There are currently approximately $111 million, or 60.30% of VSTM’s equity, in the hands of institutional investors. The three largest VSTM shareholders are: BAKER BROS. ADVISORS LP with ownership of 26,988,898, which is approximately 0% of the company’s market capitalization and approximately 1.20% of the total institutional ownership; BVF INC/IL owns 19,974,658 shares of stock with an approximate value of $20.17 million in VSTM stock; and VIKING GLOBAL INVESTORS LP, currently with $9.32 million in VSTM stock with ownership of approximately New York’s market capitalization.

Positions increased in the shares of Verastem Inc. held by institutional investors at the end of August and at the time of the August report, as 46 institutional owners consolidated their position in Verastem Inc. [NASDAQ:VSTM] About 18,963,949 shares. In addition, 76 investors decreased their positions by 25,179,373 shares, while 37 investors filled positions with 65,811.347 shares. The said changes put institutional holdings at 109,954,669 shares, according to the latest report from the Securities and Exchange Commission. VSTM’s stock included 22 new institutional investments totaling 11,590,814 shares, while 34 institutional investors sold positions worth 3,463,272 shares during the same period.

Leave A Reply

Your email address will not be published.